Award
Food and Drug Administration 5R01FD007632-04
ACCELERATE: An Efficient and Innovative Natural History Study Addressing Unmet Needs in Castleman Disease
Recipient
Joshua D. Brandstadter
Award Amount
$397,605.00
Ceiling
$397,605.00
Awarded
July 21, 2025
Identifier
5R01FD007632-04
The FDA awarded $397,605 for a natural history study on Castleman disease to identify patient subtypes and treatment approaches, led by Joshua D. Brandstadter at the University of Pennsylvania.
Description
This project involves leveraging data from a natural history study of Castleman disease to identify patient subtypes, outcome measures, and treatment approaches. The project is funded by the FDA under RFA-FD-22-001, with a total award amount of $397,605 for the fiscal year 2025. The project is led by Joshua D. Brandstadter, Program Scholar at the University of Pennsylvania, and involves collaboration with the Castleman Disease Collaborative Network and Janssen Pharmaceuticals.